Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 4
1980 10
1981 16
1982 25
1983 34
1984 22
1985 37
1986 49
1987 67
1988 51
1989 55
1990 78
1991 88
1992 132
1993 156
1994 168
1995 203
1996 208
1997 230
1998 252
1999 341
2000 359
2001 445
2002 557
2003 625
2004 881
2005 1171
2006 1355
2007 1577
2008 1855
2009 2195
2010 2474
2011 2894
2012 3458
2013 4070
2014 4739
2015 5313
2016 5761
2017 6427
2018 7476
2019 8582
2020 10065
2021 11790
2022 13974
2023 13843
2024 15866
2025 6241

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121,818 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: chen x. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JAMA. 2023. PMID: 38015220 Free PMC article. Clinical Trial.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, Chen X, Sun Y, He X, Hu C, Lin L, Yu Q, Wang S, Wang G, Lei F, Wen J, Yang K, Lin Z, Guo Y, Chen S, Huang X, Wu Y, Liang L, Chen C, Bai F, Ma X, Zhang Y, Leaw S, Zhang L, Fang W. Yang Y, et al. Among authors: chen x. Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18. Cancer Cell. 2023. PMID: 37207654 Free article. Clinical Trial.
Targeted MYC2 stabilization confers citrus Huanglongbing resistance.
Zhao P, Yang H, Sun Y, Zhang J, Gao K, Wu J, Zhu C, Yin C, Chen X, Liu Q, Xia Q, Li Q, Xiao H, Sun HX, Zhang X, Yi L, Zhou C, Kliebenstein DJ, Fang R, Wang X, Ye J. Zhao P, et al. Among authors: chen x. Science. 2025 Apr 11;388(6743):191-198. doi: 10.1126/science.adq7203. Epub 2025 Apr 10. Science. 2025. PMID: 40208996
Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.
Wang E, Zhou H, Nadorp B, Cayanan G, Chen X, Yeaton AH, Nomikou S, Witkowski MT, Narang S, Kloetgen A, Thandapani P, Ravn-Boess N, Tsirigos A, Aifantis I. Wang E, et al. Among authors: chen x. Cell Stem Cell. 2021 Apr 1;28(4):718-731.e6. doi: 10.1016/j.stem.2020.12.005. Epub 2021 Jan 14. Cell Stem Cell. 2021. PMID: 33450187 Free PMC article.
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.
Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, Chen CB, Chen XZ, Zhu XD, Yuan YW, Yang KY, Jin F, Hu WH, Xie FY, Huang Y, Han F, Tang LL, Mao YP, Lu LX, Sun R, He YX, Zhou YY, Long GX, Tang J, Chen LS, Zong JF, Jin T, Li L, Lin J, Huang J, Gong XY, Zhou GQ, Chen L, Li WF, Chen YP, Xu C, Lin L, Huang SH, Huang SW, Wang YQ, Huang CL, Feng HX, Hou M, Chen CH, Zheng SF, Li YQ, Hong SB, Jie YS, Li H, Yun JP, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Li JB, Lin AH, Liu N, Zhang Y, Guo R, Ma J, Sun Y. Liang YL, et al. Among authors: chen xz. JAMA. 2025 Mar 13:e251132. doi: 10.1001/jama.2025.1132. Online ahead of print. JAMA. 2025. PMID: 40079940
Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM.
Ito F, Li Z, Minakhin L, Chandramouly G, Tyagi M, Betsch R, Krais JJ, Taberi B, Vekariya U, Calbert M, Skorski T, Johnson N, Chen XS, Pomerantz RT. Ito F, et al. Among authors: chen xs. Nat Commun. 2024 Aug 14;15(1):7003. doi: 10.1038/s41467-024-51351-4. Nat Commun. 2024. PMID: 39143110 Free PMC article.
121,818 results
You have reached the last available page of results. Please see the User Guide for more information.